Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of the Oral TRK Inhibitor Larotrectinib in Adult Patients With Solid Tumors

Trial Profile

A Phase 1 Study of the Oral TRK Inhibitor Larotrectinib in Adult Patients With Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Larotrectinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Bayer; Loxo Oncology
  • Most Recent Events

    • 05 Nov 2019 Planned End Date changed from 31 Aug 2020 to 30 Mar 2021.
    • 30 Oct 2019 Results comparing effectiveness of Larotrectinib vs. Entrectinib in patients with non-small cell lung cancer from studies (NCT02122913, NAVIGATE, ALKA-372-001, STARTRK-1, and STARTRK-2), presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019.
    • 28 Sep 2019 According to a Bayer media release, data from this study were published at the 44th European Society for Medical Oncology (ESMO) Congress 2019, taking place September 27 to October 1 in Barcelona, Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top